Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

Cellectis, a clinical-stage biotechnology company specializing in gene editing for cell and gene therapies, has announced its Annual General Meeting (AGM) scheduled for June 26, 2025. The meeting will take place at 2:30 p.m. CET at the Biopark auditorium located in Paris, France. This year's agenda and participation information for shareholders have been detailed and are accessible on the Cellectis website.

Cellectis employs its innovative gene-editing platform to develop therapies aimed at treating life-threatening conditions, particularly focusing on oncology through an allogeneic approach for CAR T immunotherapies. The company has distinguished itself by pioneering off-the-shelf, ready-to-use gene-edited CAR T-cells, which aim to offer efficient treatment options for cancer patients. Notably, Cellectis possesses in-house manufacturing capabilities, allowing it to maintain control over the entire cell and gene therapy production process, an advantage in the competitive biotechnology landscape.

With headquarters in Paris and additional locations in New York and Raleigh, North Carolina, Cellectis is publicly traded on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS). Their commitment to advancing healthcare through innovative solutions is reflected in their strategic research and development initiatives.

For shareholders and interested parties, detailed documents relating to the AGM are available online, including the board of directors' report. Cellectis invites stakeholders to engage with the company via their investor relations contact for further inquiries. The upcoming AGM promises to be a significant event for the company's future direction and objectives in the dynamically evolving field of biotechnology.

Cellectis, a clinical-stage biotechnology company recognized for its innovative gene-editing technology, is preparing for its Annual Shareholders General Meeting on June 26, 2025. With a focus on developing cell and gene therapies, particularly through allogeneic CAR T immunotherapies, Cellectis is uniquely positioned in the biopharmaceutical landscape. Investors should closely monitor developments from this meeting, as it may set the tone for the company’s strategic direction and operational advancements.

Recent advancements in the field of gene therapy present substantial opportunities, especially with Cellectis's focus on off-the-shelf CAR T treatments that can streamline the treatment for cancer patients. This innovative approach could drive significant demand and differentiation in a competitive sector. With an in-house manufacturing capability, Cellectis controls a crucial aspect of its value chain, which enhances its operational efficiencies and market competitiveness.

Investors should pay attention to the detailed agenda and reports presented during the AGM, which will likely cover progress reports on clinical trials, updated financial forecasts, and potential partnerships or collaborations. Cellectis’s fiscal health is of particular interest; prudent management of resources amidst ongoing clinical studies is vital for sustaining momentum in this volatile sector.

Positioning amid increasing competition in the biotechnology domain, shareholders should assess how Cellectis plans to navigate these challenges. Active engagement with shareholders at the AGM could signal a commitment to transparency, potentially fostering investor confidence.

In conclusion, as Cellectis prepares for its meeting, investors should evaluate the outcomes in context with market expectations while considering the potential for future growth fueled by advancements in gene therapy. Cellectis remains a company to watch closely, particularly as it works to leverage its unique capabilities in a rapidly evolving market.